AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30402880 — intervention group
Group type: EXPERIMENTAL
Intervention: M281 (all doses)
Number of subjects: 50
Study 29439757 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Arginine containing toothpaste
Number of subjects: 60
Study 29439757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-hydroxyapatite toothpaste
Number of subjects: 60
Study 27704559 — intervention group
Group type: EXPERIMENTAL
Intervention: cTPE (Spectra Optia)
Number of subjects: 27
Study 27704559 — intervention group
Group type: COMPARATOR
Intervention: mTPE (Diapact)
Number of subjects: 27
Study 25103974 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation) applied to the stellate ganglion region, 4 times/day for 30 min/session for 5 days
Number of subjects: 38
Study 25103974 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS applied to the posterior cervical region (C7‐T4)
Number of subjects: 38
Study 22289752 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-neutrophil cytoplasmic antibody (ANCA) in the acute phase of Kawasaki disease
Number of subjects: 46
Study 22289752 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-neutrophil cytoplasmic antibody (ANCA) in the recovery phase of Kawasaki disease
Number of subjects: 46
Study 22289752 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-neutrophil cytoplasmic antibody (ANCA) status in Kawasaki disease
Number of subjects: 46
Study 21362122 — intervention group
Group type: EXPERIMENTAL
Intervention: rGLP-1 (8.5 pmol/kg/min)
Number of subjects: 47
Study 21362122 — intervention group
Group type: EXPERIMENTAL
Intervention: rGLP-1 (5.0 pmol/kg/min)
Number of subjects: 47
Study 21362122 — intervention group
Group type: EXPERIMENTAL
Intervention: rGLP-1 (2.5 pmol/kg/min)
Number of subjects: 47
Study 21362122 — intervention group
Group type: EXPERIMENTAL
Intervention: rGLP-1 (1.25 pmol/kg/min)
Number of subjects: 47
Study 21362122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 18198650 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiangyue Cream (QYC)
Number of subjects: 80
Study 18198650 — intervention group
Group type: COMPARATOR
Intervention: Halometasone cream
Number of subjects: 80
Study 15585690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (n‐3 PUFA)
Number of subjects: 0
Study 15585690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11961504 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 11961504 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 10212709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/kg
Number of subjects: 156
Study 10212709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group PP)
Number of subjects: 156
Study 8800786 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual semiquantitative (SQ) reading
Number of subjects: 400
Study 8800786 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative morphometry (QM)
Number of subjects: 400
Study 8800786 — intervention group
Group type: COMPARATOR
Intervention: Consensus reading
Number of subjects: 400
Study 2212452 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole salicylate 750 mg three times daily
Number of subjects: 38
Study 2212452 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily
Number of subjects: 38
Study 417191 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 91
Study 417191 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 91
Study 29124387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus coryniformis K8 CECT5711 (3 × 10^9 CFU/day)
Number of subjects: 98
Study 29124387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 30525347 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic inhibition of PCSK9
Number of subjects: 5359
Study 30525347 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 5359
Study 26645417 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher A's intervention
Number of subjects: 2
Study 26645417 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher B's intervention
Number of subjects: 2
Study 24374246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pneumoperitoneum pressure (LPP; 8 mm Hg)
Number of subjects: 42
Study 24374246 — intervention group
Group type: COMPARATOR
Intervention: Standard pneumoperitoneum pressure (SPP; 12 mm Hg)
Number of subjects: 42
Study 22431961 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic back pain patients with evidence for root damage
Number of subjects: 37
Study 22431961 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic back pain patients
Number of subjects: 37
Study 22431961 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 20637539 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 score > or = 35
Number of subjects: 721
Study 20637539 — intervention group
Group type: COMPARATOR
Intervention: PSA > or = 3.0 ng/ml
Number of subjects: 721
Study 20637539 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 in men with low PSA
Number of subjects: 721
Study 20637539 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA3 in men with previous negative biopsy
Number of subjects: 721
Study 17761004 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy program including shoulder joint and spinal mobilisation, soft tissue massage, postural taping, and home exercises for scapular control, posture and rotator cuff strengthening.
Number of subjects: 200
Study 17761004 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving inactive ultrasound and gentle application of an inert gel over the shoulder region.
Number of subjects: 200
Study 17761004 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy program
Number of subjects: 200
Study 17761004 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 200
Study 15269312 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PEEP (mean 13.2+/‐3.5 cm of water)
Number of subjects: 549
Study 15269312 — intervention group
Group type: COMPARATOR
Intervention: Lower PEEP (mean 8.3+/‐3.2 cm of water)
Number of subjects: 549
Study 15269312 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PEEP
Number of subjects: 549
Study 15269312 — intervention group
Group type: COMPARATOR
Intervention: Lower PEEP
Number of subjects: 549
Study 11139315 — intervention group
Group type: EXPERIMENTAL
Intervention: 5th edition TNM classification
Number of subjects: 633
Study 11139315 — intervention group
Group type: COMPARATOR
Intervention: 4th edition TNM classification
Number of subjects: 633
Study 9647940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (VIAGRA)
Number of subjects: 4274
Study 9647940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4274
Study 8073240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 8073240 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical treatments
Number of subjects: 0
Study 2799271 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel
Number of subjects: 189
Study 2799271 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat)
Number of subjects: 189
Study 2799271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric-aluminum-fluoride solution (FeAlF)
Number of subjects: 189
Study 2799271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 189
Study 1107648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocusert drug delivery system
Number of subjects: 0
Study 1107648 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine-eyedrops
Number of subjects: 0
Study 31090673 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aspirin (81 mg; single-dose)
Number of subjects: 24
Study 31090673 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic aspirin (81 mg; 14 days)
Number of subjects: 24
Study 31090673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acute)
Number of subjects: 24
Study 31090673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chronic)
Number of subjects: 24
Study 27986983 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3
Number of subjects: 305
Study 27986983 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3
Number of subjects: 305
Study 27986983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 25650370 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline 200 mg for 1 month
Number of subjects: 50
Study 25650370 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 50
Study 24824408 — intervention group
Group type: EXPERIMENTAL
Intervention: CAG repeat length
Number of subjects: 1539
Study 23250319 — intervention group
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Number of subjects: 194
Study 19382032 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day peroral iron for 2 months
Number of subjects: 20
Study 19382032 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 20
Study 17998507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 716
Study 17998507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 716
Study 17998507 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 716
Study 17998507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (both doses)
Number of subjects: 716
Study 16003697 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ST-segment deviation
Number of subjects: 69
Study 16003697 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula derived from initial ECG measurements
Number of subjects: 69
Study 16003697 — intervention group
Group type: EXPERIMENTAL
Intervention: Study population characteristics
Number of subjects: 69
Study 12418722 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0% w/v betaine with 1% SLS
Number of subjects: 25
Study 12418722 — intervention group
Group type: COMPARATOR
Intervention: 2% SLS
Number of subjects: 25
Study 12418722 — intervention group
Group type: COMPARATOR
Intervention: 2% CAPB
Number of subjects: 25
Study 12418722 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0% w/v betaine with 2% CAPB
Number of subjects: 25
Study 10353377 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 36
Study 10353377 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol condition
Number of subjects: 36
Study 8951190 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil hydrochloride and atovaquone
Number of subjects: 370
Study 1766047 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 14
Study 1766047 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion
Number of subjects: 14
Study 7051944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's iodine
Number of subjects: 44
Study 7051944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31811950 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variant rs76766811 in African Americans
Number of subjects: 4974
Study 31811950 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4974
Study 30654789 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI assessment
Number of subjects: 27955
Study 30654789 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness tests (50-m sprint run, sit-and-reach, standing-broad jump, sit-ups, pull-ups, 1000 m/boy or 800 m/girl distance run)
Number of subjects: 27955
Study 30654789 — intervention group
Group type: COMPARATOR
Intervention: Socio-economic status (SES) impact on fitness performance
Number of subjects: 27955
Study 28303471 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral pH bleaching gel (Pola Office+)
Number of subjects: 54
Study 28303471 — intervention group
Group type: COMPARATOR
Intervention: Acid pH bleaching gel (Pola Office)
Number of subjects: 54
Study 25882604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction for Breast Cancer (MBSR(BC)) program
Number of subjects: 72
Study 25882604 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 72
Study 24149738 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg·d(‐1) magnesium oxide supplementation
Number of subjects: 16
Study 24149738 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 22047450 — intervention group
Group type: EXPERIMENTAL
Intervention: Diskus (fluticasone; D-group)
Number of subjects: 100
Study 22047450 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (budesonide; T-group)
Number of subjects: 100
Study 19568054 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable dermal stapler
Number of subjects: 11
Study 19568054 — intervention group
Group type: COMPARATOR
Intervention: Dermal sutures
Number of subjects: 11
Study 17908741 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin A and zinc supplement
Number of subjects: 707
Study 17908741 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc alone
Number of subjects: 707
Study 17908741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A alone
Number of subjects: 707
Study 17908741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study 14726116 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Release (CR) tablets
Number of subjects: 12
Study 14726116 — intervention group
Group type: COMPARATOR
Intervention: Immediate Release (IR) tablets
Number of subjects: 12
Study 11159302 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram salbutamol with non-electrostatic spacers
Number of subjects: 90
Study 11159302 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microgram salbutamol with non-electrostatic spacers
Number of subjects: 90
Study 11159302 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram salbutamol with Nebuchamber, Aerochamber, and Volumatic
Number of subjects: 90
Study 11159302 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microgram salbutamol with Nebuchamber, Aerochamber, and Volumatic
Number of subjects: 90
Study 9563212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsing electromagnetic fields (1 hour per day, 5 days per week)
Number of subjects: 23
Study 9563212 — intervention group
Group type: EXPERIMENTAL
Intervention: Real pulsing electromagnetic fields (2 weeks)
Number of subjects: 23
Study 9563212 — intervention group
Group type: COMPARATOR
Intervention: Placebo pulsing electromagnetic fields (2 weeks)
Number of subjects: 23
Study 9563212 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-power pulsing electromagnetic fields
Number of subjects: 23
Study 7836491 — intervention group
Group type: EXPERIMENTAL
Intervention: High phenylalanine levels (Phe-level)
Number of subjects: 19
Study 7836491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phenylalanine levels (Phe-level)
Number of subjects: 19
Study 7836491 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects, mean age 20.7 years)
Number of subjects: 19
Study 3407601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie meal
Number of subjects: 10
Study 3407601 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie meal
Number of subjects: 10
Study 31319883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lertal Group (LG)
Number of subjects: 128
Study 31319883 — intervention group
Group type: COMPARATOR
Intervention: Observation Group (OG)
Number of subjects: 128
Study 28757571 — intervention group
Group type: EXPERIMENTAL
Intervention: Geophysical model function (GMF) and polarization ratio (PR) model for wind retrieval
Number of subjects: 16
Study 28757571 — intervention group
Group type: COMPARATOR
Intervention: Comparison with ECMWF re-analysis winds
Number of subjects: 16
Study 26145837 — intervention group
Group type: EXPERIMENTAL
Intervention: CEH‐EUS‐FNA
Number of subjects: 40
Study 26145837 — intervention group
Group type: COMPARATOR
Intervention: Conventional EUS‐FNA
Number of subjects: 40
Study 23635551 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 23
Study 23635551 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 23
Study 21181180 — intervention group
Group type: EXPERIMENTAL
Intervention: Metric view (photograph of the lesion with a surgical ruler)
Number of subjects: 30
Study 21181180 — intervention group
Group type: COMPARATOR
Intervention: Frontal view
Number of subjects: 30
Study 21181180 — intervention group
Group type: COMPARATOR
Intervention: Close-up view
Number of subjects: 30
Study 19584772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (50, 60, or 70 units for women; 60, 70, or 80 units for men)
Number of subjects: 0
Study 19584772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19584772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 0
Study 16647933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary treatment
Number of subjects: 106
Study 16647933 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal reconstructive surgery
Number of subjects: 106
Study 16647933 — intervention group
Group type: COMPARATOR
Intervention: Surgery group vs Pessary group
Number of subjects: 106
Study 15262632 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises
Number of subjects: 60
Study 15262632 — intervention group
Group type: COMPARATOR
Intervention: Open kinetic chain exercises
Number of subjects: 60
Study 11331213 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐T4 administration (100 microg/day)
Number of subjects: 82
Study 11331213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 9330779 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐181101 under fasted conditions (days 1-6)
Number of subjects: 12
Study 9330779 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐181101 under fed conditions (days 7-12)
Number of subjects: 12
Study 9330779 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐181101 administered with food
Number of subjects: 12
Study 9330779 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐181101 administered without food
Number of subjects: 12
Study 7970996 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg intravenous allopurinol
Number of subjects: 12
Study 7970996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg intravenous allopurinol
Number of subjects: 12
Study 2912911 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal (scatter) photocoagulation
Number of subjects: 0
Study 2912911 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment density (repeating photocoagulation)
Number of subjects: 0
Study 238810 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine succinate (LOX) 40-65 mg/day, b.i.d. schedule
Number of subjects: 49
Study 238810 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine hydrochloride (TFP) appropriate dosage
Number of subjects: 49
Study 30950955 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D separating, fusing, opacifying, false-coloring, and volume rendering (SFOF-VR) technique
Number of subjects: 109
Study 28478093 — intervention group
Group type: EXPERIMENTAL
Intervention: DAK
Number of subjects: 68
Study 28478093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26719316 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based WASH programme integrated with periodic mass distribution of albendazole every 6 months.
Number of subjects: 18
Study 26719316 — intervention group
Group type: COMPARATOR
Intervention: Mass deworming (albendazole) alone every 6 months.
Number of subjects: 18
Study 24090384 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium orotate and other antihypertensive, metabolic drugs, sedative and uroseptic phytotherapy, and nondrug measures
Number of subjects: 150
Study 21355153 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture combined with conventional acupuncture
Number of subjects: 80
Study 21355153 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 80
Study 19487705 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families America model prenatal intervention
Number of subjects: 238
Study 19487705 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to the intervention)
Number of subjects: 238
Study 17144787 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary medicine (including acupuncture, aromatherapy, massage, homeopathy, meditation, reflexology, herbal medicine, yoga, dietary supplements, relaxation techniques)
Number of subjects: 0
Study 15686716 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid weaning
Number of subjects: 41
Study 10971089 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography (TVS)
Number of subjects: 0
Study 10971089 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 0
Study 10971089 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological investigation
Number of subjects: 0
Study 10971089 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic control
Number of subjects: 0
Study 10971089 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive biopsy
Number of subjects: 0
Study 10971089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated curettage
Number of subjects: 0
Study 8783703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg b.i.d. for 5 days)
Number of subjects: 173
Study 8783703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 8783703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 173
Study 8783703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Placebo
Number of subjects: 173
Study 1454349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic mydriasis of the right eye
Number of subjects: 15
Study 6508263 — intervention group
Group type: EXPERIMENTAL
Intervention: Timentin (ticarcillin plus clavulanic acid)
Number of subjects: 116